---
title: "Relutrigine in SCN2A- and SCN8A-related developmental and epileptic encephalopathies: Clinical evidence"
description: "Formulary evidence on Relutrigine in SCN2A- and SCN8A-related developmental and epileptic encephalopathies: Clinical evidence. Covers EMBOLD, EMERALD, Single-patient emergency use: new zealand, Single-patient emergency use: Germany, PRAX-562-101, and PRAX-562-102. 75 evidence topics quoted from 17 sources."
canonical: "https://www.evicenter.com/drugs/relutrigine--scn2a-and-scn8a-related-developmental-and-epileptic-encephalopathies/clinical-evidence"
published: "2026-09-14T15:39:06-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Relutrigine in SCN2A- and SCN8A-related developmental and epileptic encephalopathies: Clinical evidence

<a id="clinical-evidence"></a>

## 3 Clinical Evidence

<a id="heading-3.1"></a>

### 3.1 Study Summaries

<a id="heading-3.1.1"></a>

#### 3.1.1 EMBOLD

<a id="heading-3.1.1.1"></a>

##### 3.1.1.1 Objective

<a id="topic-3.1.1.1-1"></a>

###### Initial protocol: safety, tolerability, efficacy, and pharmacokinetics

> “safety, tolerability, efficacy, and pharmacokinetics (PK)”

Source: [Pfister et al. (2023c)](https://praxismedicines.com/wp-content/uploads/2023/12/Pfister_AES2023_EMBOLD_Poster_Final.pdf)

<a id="heading-3.1.1.2"></a>

##### 3.1.1.2 Location and Study Date

Additional sources: [ClinicalTrials.gov NCT05818553](https://clinicaltrials.gov/study/NCT05818553)

<a id="heading-3.1.1.3"></a>

##### 3.1.1.3 Study Design

<a id="topic-3.1.1.3-1"></a>

###### Multicenter randomized study

> “multicenter, randomized, double-blind, placebo-controlled”

Source: [Kamireddy et al. (2026a)](https://praxismedicines.com/aan2026-10-010/)

<a id="topic-3.1.1.3-2"></a>

###### EMBOLD: confirmatory cohort study design

> “DOUBLE-BLIND TREATMENT PERIOD”
> “1:1”

Source: [Praxis Precision Medicines presentation (2025)](https://investors.praxismedicines.com/static-files/9e87e964-ab44-48df-9870-1553b639f479)

<a id="topic-3.1.1.3-3"></a>

###### Placebo-period masking

> “timing blinded to families and investigators”

Source: [Kamireddy et al. (2025a)](https://praxismedicines.com/aes138/)

<a id="topic-3.1.1.3-4"></a>

###### EMBOLD: confirmatory cohort interim analysis

> “Successful interim analysis triggered early stop for efficacy”

Source: [Praxis Precision Medicines EMBOLD results announcement (2025)](https://ir.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-announces-positive-results-embold)

<a id="heading-3.1.1.4"></a>

##### 3.1.1.4 Eligibility Criteria

<a id="topic-3.1.1.4-1"></a>

###### EMBOLD: cohort 1 age and weight criteria

> “2-18 years inclusive; weight ≥10 kg”

Source: [Frizzo et al. (2025)](https://praxismedicines.com/p157_gil-nagel_iec2025_embold-topline/)

<a id="topic-3.1.1.4-2"></a>

###### Cohort 1: genetic disease eligibility

> “Documented severe DEE with mutations in SCN2A or SCN8A genes”

Source: [Frizzo et al. (2025)](https://praxismedicines.com/p157_gil-nagel_iec2025_embold-topline/)

<a id="topic-3.1.1.4-3"></a>

###### Initial protocol: exclusion of loss-of-function variants

> “loss-of-function missense variant or a presumed LoF variant”

Source: [Pfister et al. (2023c)](https://praxismedicines.com/wp-content/uploads/2023/12/Pfister_AES2023_EMBOLD_Poster_Final.pdf)

<a id="topic-3.1.1.4-4"></a>

###### Initial protocol: SCN2A seizure-onset eligibility

> “seizure onset in first 3 months of life”

Source: [Pfister et al. (2023c)](https://praxismedicines.com/wp-content/uploads/2023/12/Pfister_AES2023_EMBOLD_Poster_Final.pdf)

<a id="heading-3.1.1.5"></a>

##### 3.1.1.5 Treatment

<a id="topic-3.1.1.5-1"></a>

###### Cohort 1 starting dose and permitted adjustment

> “0.5 mg/kg/day PRAX-562 QD”
> “Dose adjustment is permitted to a maximum of 1.0 mg/kg/day and a minimum of 0.25 mg/kg/day.”

Source: [Pfister et al. (2023c)](https://praxismedicines.com/wp-content/uploads/2023/12/Pfister_AES2023_EMBOLD_Poster_Final.pdf)

<a id="topic-3.1.1.5-2"></a>

###### EMBOLD: confirmatory cohort treatment regimens

| Regimen                          | Direct quotations                                         |
| -------------------------------- | --------------------------------------------------------- |
| Relutrigine throughout treatment | “Relutrigine for 4 x 4 weeks”                             |
| Relutrigine and placebo periods  | “Placebo for 1 x 4 weeks” · “Relutrigine for 3 x 4 weeks” |
| Dose                             | “1 mg/kg/day”                                             |

Source: [Praxis Precision Medicines presentation (2025)](https://investors.praxismedicines.com/static-files/9e87e964-ab44-48df-9870-1553b639f479)

<a id="heading-3.1.1.6"></a>

##### 3.1.1.6 Study Outcomes

<a id="heading-3.1.1.6.1"></a>

###### 3.1.1.6.1 Rationale for Using Monthly Motor Seizure Frequency as the Primary Endpoint

<a id="topic-3.1.1.6.1-1"></a>

###### Confirmatory cohort: primary outcome definition

> “Change from baseline in monthly (28 day) motor seizure frequency”

Source: [Frizzo et al. (2025)](https://praxismedicines.com/p157_gil-nagel_iec2025_embold-topline/)

<a id="topic-3.1.1.6.1-2"></a>

###### Rationale for endpoint selection

No evidence found.

<a id="heading-3.1.1.7"></a>

##### 3.1.1.7 Statistical Analysis Description

<a id="heading-3.1.1.7.1"></a>

###### 3.1.1.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.1.7.1-1"></a>

###### Initial protocol: planned enrollment

> “will enroll ≈20 eligible male and female participants aged 2-18 years, inclusive, with a diagnosis of early onset SCN2A-DEE or SCN8A-DEE”

Source: [Pfister et al. (2023c)](https://praxismedicines.com/wp-content/uploads/2023/12/Pfister_AES2023_EMBOLD_Poster_Final.pdf)

<a id="topic-3.1.1.7.1-2"></a>

###### EMBOLD: cohort 1 enrollment and efficacy population

> “Sixteen patients were randomized (1:1)”
> “Fifteen patients were determined to be eligible for efficacy assessments.”

Source: [Praxis Precision Medicines EMBOLD topline results announcement (2024)](https://investors.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-announces-positive-topline-results-0)

<a id="topic-3.1.1.7.1-3"></a>

###### EMBOLD: cohort 2 enrollment

> “Randomized (N = 53)”

Source: [Kamireddy et al. (2026a)](https://praxismedicines.com/aan2026-10-010/)

<a id="topic-3.1.1.7.1-4"></a>

###### Cohort 2: treatment-exposure analysis counts, not independent parallel groups

| Treatment exposure | Participants |
| --- | --- |
| Relutrigine | “51” |
| Placebo | “25” |

Source: [Kamireddy et al. (2026a)](https://praxismedicines.com/aan2026-10-010/)

<a id="heading-3.1.1.7.2"></a>

###### 3.1.1.7.2 Description of Analysis Sets

<a id="topic-3.1.1.7.2-1"></a>

###### Efficacy analysis population

> “All efficacy analyses were conducted in the ITT population”

Source: [Bialer et al. (2026)](https://onlinelibrary.wiley.com/doi/full/10.1002/epi.70346)

<a id="topic-3.1.1.7.2-2"></a>

###### Efficacy model: adjustment factors

> “baseline seizure frequency and exposure time”

Source: [Bialer et al. (2026)](https://onlinelibrary.wiley.com/doi/full/10.1002/epi.70346)

<a id="topic-3.1.1.7.2-3"></a>

###### Cohort 1: derivation of placebo-adjusted percentage reduction

> “log-transformed placebo-adjusted relutrigine effect”

Source: [Frizzo et al. (2025)](https://praxismedicines.com/p157_gil-nagel_iec2025_embold-topline/)

<a id="heading-3.1.1.8"></a>

##### 3.1.1.8 Results

<a id="heading-3.1.1.8.1"></a>

###### 3.1.1.8.1 Participant Disposition

<a id="topic-3.1.1.8.1-1"></a>

###### Cohort 2: discontinuations during placebo exposure

| Reason | Participants |
| --- | --- |
| Withdrawal of consent | “1” |
| Death | “1” |

Source: [Kamireddy et al. (2026a)](https://praxismedicines.com/aan2026-10-010/)

<a id="heading-3.1.1.8.2"></a>

###### 3.1.1.8.2 Baseline Characteristics

<a id="topic-3.1.1.8.2-1"></a>

###### Cohort 2: relutrigine-exposed population

| Characteristic | Value |
| --- | --- |
| Age, mean (minimum, maximum), years | “6.0 (1, 18)” |
| SCN2A, participants (%) | “13 (25%)” |
| SCN8A, participants (%) | “38 (75%)” |

Source: [Kamireddy et al. (2026a)](https://praxismedicines.com/aan2026-10-010/)

<a id="heading-3.1.1.8.3"></a>

###### 3.1.1.8.3 Efficacy Results

<a id="topic-3.1.1.8.3-1"></a>

###### EMBOLD: primary efficacy results, first and confirmatory cohorts

> “Relutrigine demonstrated placebo-adjusted seizure reduction in 16 weeks of 46% (p=0.0354) in the first cohort and 53% (p<0.0002) in the confirmatory, registration cohort”

Source: [Kamireddy et al. (2025a)](https://praxismedicines.com/aes138/)

<a id="topic-3.1.1.8.3-2"></a>

###### EMBOLD: cohort 1 seizure-freedom report at 16 weeks

> “33% of patients were seizure-free”

Source: [Frizzo et al. (2025)](https://praxismedicines.com/p157_gil-nagel_iec2025_embold-topline/)

<a id="topic-3.1.1.8.3-3"></a>

###### EMBOLD: open-label extension

> “OLE data through 11 months support sustained seizure reduction (90%, n=13)”
> “mean longest period without seizures, 67 days vs. 3 at baseline”

Source: [Kamireddy et al. (2025b)](https://aesnet.org/abstractslisting/relutrigine-demonstrates-sustained-seizure-reduction-with-continued-exposure-on-top-of-standard-of-care-results-from-the-embold-open-label-extension)

<a id="topic-3.1.1.8.3-4"></a>

###### EMBOLD cohort 2: motor seizure-free days

| “Key Secondary”           | Estimate | p-value |
| ------------------------- | ---------: | --------: |
| Motor seizure-free days |   “+66.2%” |  “0.0340” |

Source: [Kamireddy et al. (2026a)](https://praxismedicines.com/aan2026-10-010/)

<a id="heading-3.1.1.8.4"></a>

###### 3.1.1.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.1.8.4-1"></a>

###### EMBOLD cohort 2: clinician and caregiver global improvement

| “Key Secondary”           | Estimate | p-value |
| ------------------------- | ---------: | --------: |
| CGI-I (Clinician)       |    “-2.62” | “<0.0001” |
| CgGI-I (Caregiver)      |     “-3.7” |   “0.002” |

Source: [Kamireddy et al. (2026a)](https://praxismedicines.com/aan2026-10-010/)

<a id="topic-3.1.1.8.4-2"></a>

###### Relutrigine-specific health-related quality-of-life instrument results

No evidence found.

<a id="heading-3.1.1.8.5"></a>

###### 3.1.1.8.5 Safety Results

<a id="topic-3.1.1.8.5-1"></a>

###### EMBOLD: cohort 1 most common adverse events

> “infections, vomiting, pyrexia, somnolence and constipation”

Source: [Praxis Precision Medicines EMBOLD topline results announcement (2024)](https://investors.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-announces-positive-topline-results-0)

<a id="topic-3.1.1.8.5-2"></a>

###### EMBOLD: cohort 1 serious adverse events

> “All SAEs determined to be not drug-related and were consistent with disease background.”

Source: [Frizzo et al. (2025)](https://praxismedicines.com/p157_gil-nagel_iec2025_embold-topline/)

<a id="topic-3.1.1.8.5-3"></a>

###### Cohort 2: adverse-event severity

> “TEAEs were mostly mild to moderate.”

Source: [Kamireddy et al. (2026a)](https://praxismedicines.com/aan2026-10-010/)

<a id="topic-3.1.1.8.5-4"></a>

###### Cohort 2: adverse event leading to discontinuation during relutrigine exposure

> “1 patient randomized to placebo arm discontinued while in relutrigine period due to an AE”

Source: [Kamireddy et al. (2026a)](https://praxismedicines.com/aan2026-10-010/)

<a id="heading-3.1.1.9"></a>

##### 3.1.1.9 Study Limitations

<a id="topic-3.1.1.9-1"></a>

###### Summary

Cohort 1 randomized 16 participants, with 15 eligible for efficacy assessment. Cohort 2 randomized 53 participants and stopped early after an efficacy interim analysis. Its relutrigine and placebo exposure populations overlap because some participants received both treatments during masked periods; the exposure counts should not be interpreted as independent parallel groups. The extension result at 11 months concerns 13 participants without a concurrent placebo comparison. Clinician and caregiver global-improvement scales are reported, but they should not be treated as equivalent to a direct health-related quality-of-life measure.

Source: [Praxis Precision Medicines EMBOLD topline results announcement (2024)](https://investors.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-announces-positive-topline-results-0); [Kamireddy et al. (2026a)](https://praxismedicines.com/aan2026-10-010/); [Praxis Precision Medicines EMBOLD results announcement (2025)](https://ir.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-announces-positive-results-embold); [Kamireddy et al. (2025a)](https://praxismedicines.com/aes138/); [Kamireddy et al. (2025b)](https://aesnet.org/abstractslisting/relutrigine-demonstrates-sustained-seizure-reduction-with-continued-exposure-on-top-of-standard-of-care-results-from-the-embold-open-label-extension)

<a id="heading-3.1.2"></a>

#### 3.1.2 EMERALD

<a id="heading-3.1.2.1"></a>

##### 3.1.2.1 Objective

Additional sources: [Kamireddy et al. (2026b)](https://praxismedicines.com/aan2026-10-009/)

<a id="heading-3.1.2.2"></a>

##### 3.1.2.2 Location and Study Date

<a id="topic-3.1.2.2-1"></a>

###### Countries recruiting in the protocol presentation

| Country |
| --- |
| “United States” |
| “Brazil” |
| “Australia” |

Source: [Kamireddy et al. (2026b)](https://praxismedicines.com/aan2026-10-009/)

<a id="topic-3.1.2.2-2"></a>

###### Actual study start and completion dates

No evidence found.

<a id="heading-3.1.2.3"></a>

##### 3.1.2.3 Study Design

<a id="topic-3.1.2.3-1"></a>

###### Phase 3 study design

> “randomized, multi-center, double-blind, placebo-controlled”

Source: [Kamireddy et al. (2026b)](https://praxismedicines.com/aan2026-10-009/)

<a id="topic-3.1.2.3-2"></a>

###### Randomization ratio

> “1:1”

Source: [Kamireddy et al. (2026b)](https://praxismedicines.com/aan2026-10-009/)

<a id="heading-3.1.2.4"></a>

##### 3.1.2.4 Eligibility Criteria

<a id="topic-3.1.2.4-1"></a>

###### Age at screening

> “2-65 years of age”

Source: [Kamireddy et al. (2026b)](https://praxismedicines.com/aan2026-10-009/)

<a id="heading-3.1.2.5"></a>

##### 3.1.2.5 Treatment

<a id="topic-3.1.2.5-1"></a>

###### Relutrigine starting dose

> “1 mg/kg/day”

Source: [Kamireddy et al. (2026b)](https://praxismedicines.com/aan2026-10-009/)

<a id="heading-3.1.2.6"></a>

##### 3.1.2.6 Study Outcomes

<a id="heading-3.1.2.6.1"></a>

###### 3.1.2.6.1 Rationale for Using Monthly Motor Seizure Frequency as the Primary Endpoint

<a id="topic-3.1.2.6.1-1"></a>

###### Primary outcome definition

> “Change from baseline in monthly motor seizure frequency”

Source: [Kamireddy et al. (2026b)](https://praxismedicines.com/aan2026-10-009/)

<a id="topic-3.1.2.6.1-2"></a>

###### Rationale for endpoint selection

No evidence found.

<a id="heading-3.1.2.7"></a>

##### 3.1.2.7 Statistical Analysis Description

<a id="heading-3.1.2.7.1"></a>

###### 3.1.2.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.2.7.1-1"></a>

###### Protocol presentation: planned enrollment

> “enrolling ~160 eligible male and female participants aged 2-65 years with a diagnosis of DEE and onset of seizures <12 years old”

Source: [Kamireddy et al. (2026b)](https://praxismedicines.com/aan2026-10-009/)

<a id="topic-3.1.2.7.1-2"></a>

###### EMERALD: enrollment update

> “approximately 200 patients enrolled”

Source: [Praxis Precision Medicines second quarter 2026 results announcement (2026)](https://www.globenewswire.com/news-release/2026/08/06/3340217/0/en/praxis-precision-medicines-provides-corporate-update-and-reports-second-quarter-2026-financial-results.html)

<a id="topic-3.1.2.7.1-3"></a>

###### Analyzed population

No evidence found.

<a id="heading-3.1.2.7.2"></a>

###### 3.1.2.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.2.8"></a>

##### 3.1.2.8 Results

<a id="heading-3.1.2.8.1"></a>

###### 3.1.2.8.1 Participant Disposition

<a id="topic-3.1.2.8.1-1"></a>

###### EMERALD: development status

> “The EMERALD study, which is evaluating relutrigine in patients with broad DEEs, has completed recruitment, with topline results anticipated in the fourth quarter of 2026.”

Source: [Praxis Precision Medicines first quarter 2026 Form 10-Q (2026)](https://praxismedicines.gcs-web.com/static-files/b0705ab1-8493-4133-b5a3-366f9912cccd)

<a id="heading-3.1.2.8.2"></a>

###### 3.1.2.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.2.8.3"></a>

###### 3.1.2.8.3 Efficacy Results

No evidence found.

<a id="heading-3.1.2.8.4"></a>

###### 3.1.2.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.2.8.5"></a>

###### 3.1.2.8.5 Safety Results

No evidence found.

<a id="heading-3.1.2.9"></a>

##### 3.1.2.9 Study Limitations

<a id="topic-3.1.2.9-1"></a>

###### Summary

The protocol presentation planned approximately 160 participants, while the subsequent corporate update reported approximately 200 enrolled. The study includes a broader DEE population than the indication addressed in this report. Recruitment completion and a planned fourth-quarter 2026 topline announcement do not establish efficacy or safety results, and the report contains no analyzed outcome dataset for EMERALD.

Source: [Kamireddy et al. (2026b)](https://praxismedicines.com/aan2026-10-009/); [Praxis Precision Medicines second quarter 2026 results announcement (2026)](https://www.globenewswire.com/news-release/2026/08/06/3340217/0/en/praxis-precision-medicines-provides-corporate-update-and-reports-second-quarter-2026-financial-results.html); [Praxis Precision Medicines first quarter 2026 Form 10-Q (2026)](https://praxismedicines.gcs-web.com/static-files/b0705ab1-8493-4133-b5a3-366f9912cccd)

<a id="heading-3.1.3"></a>

#### 3.1.3 Single-patient emergency use: New Zealand

<a id="heading-3.1.3.1"></a>

##### 3.1.3.1 Objective

Additional sources: [Andersen et al. (2025)](https://praxismedicines.com/p158_spar_iec2025_nz-eap/)

<a id="heading-3.1.3.2"></a>

##### 3.1.3.2 Location and Study Date

<a id="topic-3.1.3.2-1"></a>

###### New Zealand case: treatment initiation

> “An infant with SCN2A-DEE began receiving relutrigine in February 2024 at age 4 months”

Source: [Andersen et al. (2025)](https://praxismedicines.com/p158_spar_iec2025_nz-eap/)

<a id="heading-3.1.3.3"></a>

##### 3.1.3.3 Study Design

Additional sources: [Andersen et al. (2025)](https://praxismedicines.com/p158_spar_iec2025_nz-eap/)

<a id="heading-3.1.3.4"></a>

##### 3.1.3.4 Eligibility Criteria

Additional sources: [Andersen et al. (2025)](https://praxismedicines.com/p158_spar_iec2025_nz-eap/)

<a id="heading-3.1.3.5"></a>

##### 3.1.3.5 Treatment

<a id="topic-3.1.3.5-1"></a>

###### Starting daily dose

> “0.5 mg/kg/day”

Source: [Andersen et al. (2025)](https://praxismedicines.com/p158_spar_iec2025_nz-eap/)

<a id="heading-3.1.3.6"></a>

##### 3.1.3.6 Study Outcomes

<a id="heading-3.1.3.6.1"></a>

###### 3.1.3.6.1 Rationale for Using Motor Seizure Frequency as the Reported Outcome

Not applicable.

<a id="heading-3.1.3.7"></a>

##### 3.1.3.7 Statistical Analysis Description

<a id="heading-3.1.3.7.1"></a>

###### 3.1.3.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.3.7.1-1"></a>

###### Single treated infant

> “An infant with SCN2A-DEE began receiving relutrigine in February 2024 at age 4 months”

Source: [Andersen et al. (2025)](https://praxismedicines.com/p158_spar_iec2025_nz-eap/)

<a id="heading-3.1.3.7.2"></a>

###### 3.1.3.7.2 Description of Analysis Sets

Not applicable.

<a id="heading-3.1.3.8"></a>

##### 3.1.3.8 Results

<a id="heading-3.1.3.8.1"></a>

###### 3.1.3.8.1 Participant Disposition

Additional sources: [Andersen et al. (2025)](https://praxismedicines.com/p158_spar_iec2025_nz-eap/)

<a id="heading-3.1.3.8.2"></a>

###### 3.1.3.8.2 Baseline Characteristics

<a id="topic-3.1.3.8.2-1"></a>

###### Diagnosis and age at treatment initiation

> “An infant with SCN2A-DEE began receiving relutrigine in February 2024 at age 4 months”

Source: [Andersen et al. (2025)](https://praxismedicines.com/p158_spar_iec2025_nz-eap/)

<a id="heading-3.1.3.8.3"></a>

###### 3.1.3.8.3 Efficacy Results

<a id="topic-3.1.3.8.3-1"></a>

###### Single-patient emergency use: SCN2A-DEE, New Zealand

> “>50% reduction in seizures at 3mg/kg/day”

Source: [Andersen et al. (2025)](https://praxismedicines.com/p158_spar_iec2025_nz-eap/)

<a id="heading-3.1.3.8.4"></a>

###### 3.1.3.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.3.8.4-1"></a>

###### Clinical observation of alertness and responsiveness

> “the patient has been more alert and awake, responding to, and looking towards, familiar voices.”

Source: [Andersen et al. (2025)](https://praxismedicines.com/p158_spar_iec2025_nz-eap/)

<a id="heading-3.1.3.8.5"></a>

###### 3.1.3.8.5 Safety Results

<a id="topic-3.1.3.8.5-1"></a>

###### Reported adverse-event findings

> “no drug-related or severe adverse events.”

Source: [Andersen et al. (2025)](https://praxismedicines.com/p158_spar_iec2025_nz-eap/)

<a id="heading-3.1.3.9"></a>

##### 3.1.3.9 Study Limitations

<a id="topic-3.1.3.9-1"></a>

###### Summary

This report describes one participant treated from four months of age. The observations are uncontrolled, and the reported seizure reduction at 3 mg/kg/day cannot establish comparative effectiveness or population-level safety. Alertness and responsiveness are clinical observations, not a randomized assessment of health-related quality of life.

Source: [Andersen et al. (2025)](https://praxismedicines.com/p158_spar_iec2025_nz-eap/)

<a id="heading-3.1.4"></a>

#### 3.1.4 Single-patient emergency use: Germany

<a id="heading-3.1.4.1"></a>

##### 3.1.4.1 Objective

Additional sources: [Wagner et al. (2026)](https://praxismedicines.com/wp-content/uploads/2026/04/Petrou_AAN2026_Combo-Germany-Case.pdf)

<a id="heading-3.1.4.2"></a>

##### 3.1.4.2 Location and Study Date

<a id="topic-3.1.4.2-1"></a>

###### Treating center location

> “Munich, Germany”

Source: [Wagner et al. (2026)](https://praxismedicines.com/wp-content/uploads/2026/04/Petrou_AAN2026_Combo-Germany-Case.pdf)

<a id="topic-3.1.4.2-2"></a>

###### Exact date of relutrigine initiation

No evidence found.

<a id="heading-3.1.4.3"></a>

##### 3.1.4.3 Study Design

Additional sources: [Wagner et al. (2026)](https://praxismedicines.com/wp-content/uploads/2026/04/Petrou_AAN2026_Combo-Germany-Case.pdf)

<a id="heading-3.1.4.4"></a>

##### 3.1.4.4 Eligibility Criteria

Additional sources: [Wagner et al. (2026)](https://praxismedicines.com/wp-content/uploads/2026/04/Petrou_AAN2026_Combo-Germany-Case.pdf)

<a id="heading-3.1.4.5"></a>

##### 3.1.4.5 Treatment

<a id="topic-3.1.4.5-1"></a>

###### Adjunctive relutrigine dose

> “relutrigine (0.5 mg/kg daily dose)”

Source: [Wagner et al. (2026)](https://praxismedicines.com/wp-content/uploads/2026/04/Petrou_AAN2026_Combo-Germany-Case.pdf)

<a id="heading-3.1.4.6"></a>

##### 3.1.4.6 Study Outcomes

<a id="heading-3.1.4.6.1"></a>

###### 3.1.4.6.1 Rationale for Using Seizure Frequency as the Reported Outcome

Not applicable.

<a id="heading-3.1.4.7"></a>

##### 3.1.4.7 Statistical Analysis Description

<a id="heading-3.1.4.7.1"></a>

###### 3.1.4.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.4.7.1-1"></a>

###### Case population

> “A preterm infant”

Source: [Wagner et al. (2026)](https://praxismedicines.com/wp-content/uploads/2026/04/Petrou_AAN2026_Combo-Germany-Case.pdf)

<a id="heading-3.1.4.7.2"></a>

###### 3.1.4.7.2 Description of Analysis Sets

Not applicable.

<a id="heading-3.1.4.8"></a>

##### 3.1.4.8 Results

<a id="heading-3.1.4.8.1"></a>

###### 3.1.4.8.1 Participant Disposition

Additional sources: [Wagner et al. (2026)](https://praxismedicines.com/wp-content/uploads/2026/04/Petrou_AAN2026_Combo-Germany-Case.pdf)

<a id="heading-3.1.4.8.2"></a>

###### 3.1.4.8.2 Baseline Characteristics

<a id="topic-3.1.4.8.2-1"></a>

###### Gestational age

> “29+4 weeks gestation”

Source: [Wagner et al. (2026)](https://praxismedicines.com/wp-content/uploads/2026/04/Petrou_AAN2026_Combo-Germany-Case.pdf)

<a id="heading-3.1.4.8.3"></a>

###### 3.1.4.8.3 Efficacy Results

<a id="topic-3.1.4.8.3-1"></a>

###### Seizure frequency after adjunctive relutrigine

> “as low as 2 seizures per hour”

Source: [Wagner et al. (2026)](https://praxismedicines.com/wp-content/uploads/2026/04/Petrou_AAN2026_Combo-Germany-Case.pdf)

<a id="topic-3.1.4.8.3-2"></a>

###### Emergency-use case: antisense oligonucleotide treatment combined with precision sodium channel modulation

> “Continued improvement in clinical status permitted a previously unattainable reduction in carbamazepine dosage.”

Source: [Wagner et al. (2026)](https://praxismedicines.com/wp-content/uploads/2026/04/Petrou_AAN2026_Combo-Germany-Case.pdf)

<a id="heading-3.1.4.8.4"></a>

###### 3.1.4.8.4 Health-related Quality of Life and Patient-reported Outcomes

Additional sources: [Wagner et al. (2026)](https://praxismedicines.com/wp-content/uploads/2026/04/Petrou_AAN2026_Combo-Germany-Case.pdf)

<a id="heading-3.1.4.8.5"></a>

###### 3.1.4.8.5 Safety Results

<a id="topic-3.1.4.8.5-1"></a>

###### Safety after adjunctive relutrigine

> “no new safety findings”

Source: [Wagner et al. (2026)](https://praxismedicines.com/wp-content/uploads/2026/04/Petrou_AAN2026_Combo-Germany-Case.pdf)

<a id="heading-3.1.4.9"></a>

##### 3.1.4.9 Study Limitations

<a id="topic-3.1.4.9-1"></a>

###### Summary

This is one emergency-use case, not a randomized study. Relutrigine was used in a treatment course that also included an antisense oligonucleotide and carbamazepine. The report therefore does not isolate the effect of relutrigine from other treatment changes, and the reduction in carbamazepine dosage should not be interpreted as proof of efficacy for relutrigine alone.

Source: [Wagner et al. (2026)](https://praxismedicines.com/wp-content/uploads/2026/04/Petrou_AAN2026_Combo-Germany-Case.pdf)

<a id="heading-3.1.5"></a>

#### 3.1.5 PRAX-562-101

<a id="heading-3.1.5.1"></a>

##### 3.1.5.1 Objective

Additional sources: [Pfister et al. (2023b)](https://praxismedicines.com/wp-content/uploads/2023/09/IEC2023_562-101_Final_QRcode.pdf)

<a id="heading-3.1.5.2"></a>

##### 3.1.5.2 Location and Study Date

No evidence found.

<a id="heading-3.1.5.3"></a>

##### 3.1.5.3 Study Design

<a id="topic-3.1.5.3-1"></a>

###### Parts A and B: ascending-dose study

> “randomized, placebo-controlled”

Source: [Pfister et al. (2023b)](https://praxismedicines.com/wp-content/uploads/2023/09/IEC2023_562-101_Final_QRcode.pdf)

<a id="topic-3.1.5.3-2"></a>

###### Part C: food-effect study

> “open-label, randomized, crossover”

Source: [Pfister et al. (2023b)](https://praxismedicines.com/wp-content/uploads/2023/09/IEC2023_562-101_Final_QRcode.pdf)

<a id="heading-3.1.5.4"></a>

##### 3.1.5.4 Eligibility Criteria

<a id="topic-3.1.5.4-1"></a>

###### Healthy-adult age range

> “healthy adults aged 18-55 years”

Source: [Pfister et al. (2023b)](https://praxismedicines.com/wp-content/uploads/2023/09/IEC2023_562-101_Final_QRcode.pdf)

<a id="heading-3.1.5.5"></a>

##### 3.1.5.5 Treatment

<a id="topic-3.1.5.5-1"></a>

###### Dose ranges and food-effect dose

| Study part | Dose |
| --- | --- |
| Part A, single dose | “2.5 to 150 mg” |
| Part B, repeated once-daily dosing | “30 to 120 mg” |
| Part C, fed and fasted dosing | “90 mg” |

Source: [Pfister et al. (2023b)](https://praxismedicines.com/wp-content/uploads/2023/09/IEC2023_562-101_Final_QRcode.pdf)

<a id="heading-3.1.5.6"></a>

##### 3.1.5.6 Study Outcomes

<a id="heading-3.1.5.6.1"></a>

###### 3.1.5.6.1 Rationale for Using Safety and Tolerability as the Primary Endpoint

Not applicable.

<a id="heading-3.1.5.7"></a>

##### 3.1.5.7 Statistical Analysis Description

<a id="heading-3.1.5.7.1"></a>

###### 3.1.5.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.5.7.1-1"></a>

###### Total enrollment

> “112 participants were enrolled across the PRAX-562-101 trial (n=88 PRAX-562, n=24 placebo)”

Source: [Pfister et al. (2023b)](https://praxismedicines.com/wp-content/uploads/2023/09/IEC2023_562-101_Final_QRcode.pdf)

<a id="heading-3.1.5.7.2"></a>

###### 3.1.5.7.2 Description of Analysis Sets

<a id="topic-3.1.5.7.2-1"></a>

###### Safety analysis sets: inclusion of all participants

> “All participants were included”

Source: [Pfister et al. (2023b)](https://praxismedicines.com/wp-content/uploads/2023/09/IEC2023_562-101_Final_QRcode.pdf)

<a id="heading-3.1.5.8"></a>

##### 3.1.5.8 Results

<a id="heading-3.1.5.8.1"></a>

###### 3.1.5.8.1 Participant Disposition

Additional sources: [Pfister et al. (2023b)](https://praxismedicines.com/wp-content/uploads/2023/09/IEC2023_562-101_Final_QRcode.pdf)

<a id="heading-3.1.5.8.2"></a>

###### 3.1.5.8.2 Baseline Characteristics

Additional sources: [Pfister et al. (2023b)](https://praxismedicines.com/wp-content/uploads/2023/09/IEC2023_562-101_Final_QRcode.pdf)

<a id="heading-3.1.5.8.3"></a>

###### 3.1.5.8.3 Efficacy Results

Not applicable.

<a id="heading-3.1.5.8.4"></a>

###### 3.1.5.8.4 Health-related Quality of Life and Patient-reported Outcomes

Not applicable.

<a id="heading-3.1.5.8.5"></a>

###### 3.1.5.8.5 Safety Results

<a id="topic-3.1.5.8.5-1"></a>

###### Severe treatment-emergent adverse events

> “No severe TEAEs were reported”

Source: [Pfister et al. (2023b)](https://praxismedicines.com/wp-content/uploads/2023/09/IEC2023_562-101_Final_QRcode.pdf)

<a id="heading-3.1.5.9"></a>

##### 3.1.5.9 Study Limitations

<a id="topic-3.1.5.9-1"></a>

###### Summary

The study enrolled 112 healthy-adult participants rather than participants with SCN2A- or SCN8A-related DEE. Single-dose, repeated-dose, and food-effect findings inform pharmacokinetics and short-term tolerability, but do not establish seizure efficacy, pediatric effectiveness, or long-term safety in the target population.

Source: [Pfister et al. (2023b)](https://praxismedicines.com/wp-content/uploads/2023/09/IEC2023_562-101_Final_QRcode.pdf)

<a id="heading-3.1.6"></a>

#### 3.1.6 PRAX-562-102

<a id="heading-3.1.6.1"></a>

##### 3.1.6.1 Objective

<a id="topic-3.1.6.1-1"></a>

###### Healthy-adult pharmacology objectives

> “pharmacokinetics (PK) and pharmacodynamics (PD)”

Source: [Pfister et al. (2023a)](https://praxismedicines.com/wp-content/uploads/2024/07/IEC2023_562-102_Final_QRcode.pdf)

<a id="heading-3.1.6.2"></a>

##### 3.1.6.2 Location and Study Date

No evidence found.

<a id="heading-3.1.6.3"></a>

##### 3.1.6.3 Study Design

<a id="topic-3.1.6.3-1"></a>

###### Phase 1 design

> “randomized, placebo-controlled Phase 1 trial”

Source: [Pfister et al. (2023a)](https://praxismedicines.com/wp-content/uploads/2024/07/IEC2023_562-102_Final_QRcode.pdf)

<a id="heading-3.1.6.4"></a>

##### 3.1.6.4 Eligibility Criteria

<a id="topic-3.1.6.4-1"></a>

###### Healthy-participant age range

> “18-55 years”

Source: [Pfister et al. (2023a)](https://praxismedicines.com/wp-content/uploads/2024/07/IEC2023_562-102_Final_QRcode.pdf)

<a id="heading-3.1.6.5"></a>

##### 3.1.6.5 Treatment

<a id="topic-3.1.6.5-1"></a>

###### Part A: relutrigine daily dose and treatment duration

| Characteristic | Value |
| --- | --- |
| Once-daily dose | “90 mg” |
| Duration | “28 days” |

Source: [Pfister et al. (2023a)](https://praxismedicines.com/wp-content/uploads/2024/07/IEC2023_562-102_Final_QRcode.pdf)

<a id="topic-3.1.6.5-2"></a>

###### PRAX-562-102: phase 1 healthy-volunteer study, oxcarbazepine combination, part B treatment

> “OXC + PRAX-562 120 mg”

Source: [Pfister et al. (2023a)](https://praxismedicines.com/wp-content/uploads/2024/07/IEC2023_562-102_Final_QRcode.pdf)

<a id="heading-3.1.6.6"></a>

##### 3.1.6.6 Study Outcomes

<a id="heading-3.1.6.6.1"></a>

###### 3.1.6.6.1 Rationale for Using Safety and Tolerability as the Primary Endpoint

Not applicable.

<a id="heading-3.1.6.7"></a>

##### 3.1.6.7 Statistical Analysis Description

<a id="heading-3.1.6.7.1"></a>

###### 3.1.6.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.6.7.1-1"></a>

###### Enrollment by study part

| Population | Participants |
| --- | --- |
| Total | “48” |
| Part A | “30” |
| Part B | “18” |

Source: [Pfister et al. (2023a)](https://praxismedicines.com/wp-content/uploads/2024/07/IEC2023_562-102_Final_QRcode.pdf)

<a id="heading-3.1.6.7.2"></a>

###### 3.1.6.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.6.8"></a>

##### 3.1.6.8 Results

<a id="heading-3.1.6.8.1"></a>

###### 3.1.6.8.1 Participant Disposition

<a id="topic-3.1.6.8.1-1"></a>

###### PRAX-562-102: early termination of the combination part

> “Part B was stopped early”

Source: [Pfister et al. (2023a)](https://praxismedicines.com/wp-content/uploads/2024/07/IEC2023_562-102_Final_QRcode.pdf)

<a id="heading-3.1.6.8.2"></a>

###### 3.1.6.8.2 Baseline Characteristics

<a id="topic-3.1.6.8.2-1"></a>

###### Part A: age, mean (minimum, maximum), years

| Treatment | Age |
| --- | --- |
| Relutrigine | “38.7 (22, 53)” |
| Placebo | “37.3 (24, 49)” |

Source: [Pfister et al. (2023a)](https://praxismedicines.com/wp-content/uploads/2024/07/IEC2023_562-102_Final_QRcode.pdf)

<a id="heading-3.1.6.8.3"></a>

###### 3.1.6.8.3 Efficacy Results

Not applicable.

<a id="heading-3.1.6.8.4"></a>

###### 3.1.6.8.4 Health-related Quality of Life and Patient-reported Outcomes

Not applicable.

<a id="heading-3.1.6.8.5"></a>

###### 3.1.6.8.5 Safety Results

<a id="topic-3.1.6.8.5-1"></a>

###### PRAX-562-102: serious adverse events and study termination

> “One Part B participant experienced 3 study drug related SAEs leading to study drug discontinuation.”
> “Part B was stopped early”

Source: [Pfister et al. (2023a)](https://praxismedicines.com/wp-content/uploads/2024/07/IEC2023_562-102_Final_QRcode.pdf)

<a id="heading-3.1.6.9"></a>

##### 3.1.6.9 Study Limitations

<a id="topic-3.1.6.9-1"></a>

###### Summary

This healthy-volunteer study enrolled 48 participants, with 30 in Part A and 18 in Part B. The 28-day treatment design does not establish long-term safety or therapeutic efficacy in pediatric DEE. One participant in the oxcarbazepine combination part experienced three study-drug-related serious adverse events, and Part B stopped early. Findings from that combination and dose should be distinguished from the separate EMBOLD pediatric regimen.

Source: [Pfister et al. (2023a)](https://praxismedicines.com/wp-content/uploads/2024/07/IEC2023_562-102_Final_QRcode.pdf); [Praxis Precision Medicines presentation (2025)](https://investors.praxismedicines.com/static-files/9e87e964-ab44-48df-9870-1553b639f479)

## Related pages
- [Relutrigine: SCN2A- and SCN8A-related developmental and epileptic encephalopathies](https://www.evicenter.com/drugs/relutrigine--scn2a-and-scn8a-related-developmental-and-epileptic-encephalopathies) · [Markdown](https://www.evicenter.com/drugs/relutrigine--scn2a-and-scn8a-related-developmental-and-epileptic-encephalopathies.md)
- [Relutrigine in SCN2A- and SCN8A-related developmental and epileptic encephalopathies: Terms and abbreviations](https://www.evicenter.com/drugs/relutrigine--scn2a-and-scn8a-related-developmental-and-epileptic-encephalopathies/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/relutrigine--scn2a-and-scn8a-related-developmental-and-epileptic-encephalopathies/terms-and-abbreviations.md)
- [Relutrigine: SCN2A- and SCN8A-related developmental and epileptic encephalopathies](https://www.evicenter.com/drugs/relutrigine--scn2a-and-scn8a-related-developmental-and-epileptic-encephalopathies/executive-summary) · [Markdown](https://www.evicenter.com/drugs/relutrigine--scn2a-and-scn8a-related-developmental-and-epileptic-encephalopathies/executive-summary.md)
- [Relutrigine in SCN2A- and SCN8A-related developmental and epileptic encephalopathies: Product information and disease description](https://www.evicenter.com/drugs/relutrigine--scn2a-and-scn8a-related-developmental-and-epileptic-encephalopathies/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/relutrigine--scn2a-and-scn8a-related-developmental-and-epileptic-encephalopathies/product-information-and-disease-description.md)
- [Relutrigine in SCN2A- and SCN8A-related developmental and epileptic encephalopathies: Economic information and modeling report](https://www.evicenter.com/drugs/relutrigine--scn2a-and-scn8a-related-developmental-and-epileptic-encephalopathies/economics) · [Markdown](https://www.evicenter.com/drugs/relutrigine--scn2a-and-scn8a-related-developmental-and-epileptic-encephalopathies/economics.md)
- [Relutrigine in SCN2A- and SCN8A-related developmental and epileptic encephalopathies: References](https://www.evicenter.com/drugs/relutrigine--scn2a-and-scn8a-related-developmental-and-epileptic-encephalopathies/references) · [Markdown](https://www.evicenter.com/drugs/relutrigine--scn2a-and-scn8a-related-developmental-and-epileptic-encephalopathies/references.md)
- [Relutrigine in SCN2A- and SCN8A-related developmental and epileptic encephalopathies: prevalence by geography](https://www.evicenter.com/drugs/relutrigine--scn2a-and-scn8a-related-developmental-and-epileptic-encephalopathies/prevalence) · [Markdown](https://www.evicenter.com/drugs/relutrigine--scn2a-and-scn8a-related-developmental-and-epileptic-encephalopathies/prevalence.md)
- [Relutrigine in SCN2A- and SCN8A-related developmental and epileptic encephalopathies: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/relutrigine--scn2a-and-scn8a-related-developmental-and-epileptic-encephalopathies/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/relutrigine--scn2a-and-scn8a-related-developmental-and-epileptic-encephalopathies/cost-effectiveness-analyses.md)
